These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10094648)

  • 21. Bradykinin-receptor antagonist icatibant: possible treatment for ACE inhibitor-related angio-oedema.
    Manders K; van Deuren M; Hoedemaekers C; Simon A
    Neth J Med; 2012 Oct; 70(8):386-7. PubMed ID: 23065991
    [No Abstract]   [Full Text] [Related]  

  • 22. Development and pharmacology of angiotensin converting enzyme inhibitors.
    Antonaccio MJ
    J Pharmacol; 1983; 14 Suppl 3():29-45. PubMed ID: 6323887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin in essential hypertension.
    Atlas SA; Case DB
    Clin Endocrinol Metab; 1981 Nov; 10(3):537-75. PubMed ID: 6124330
    [No Abstract]   [Full Text] [Related]  

  • 24. [The clinical pharmacology of hypotensive agents. Angiotensin-converting enzyme inhibitors].
    Chekman IS
    Lik Sprava; 1998 Jun; (4):22-6. PubMed ID: 9784696
    [No Abstract]   [Full Text] [Related]  

  • 25. Combination of β Adrenergic Receptor Block and Renin-Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension.
    Lezama-Martínez D; Valencia-Hernández I; Flores-Monroy J; Martínez-Aguilar L
    Dose Response; 2017; 15(4):1559325817737932. PubMed ID: 29162996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No sex-related pharmacokinetic and pharmacodynamic differences of captopril.
    Massana E; Barbanoj MJ; Moros C; Morte A; Gich I; Jané F
    Pharmacol Res; 1997 Jul; 36(1):41-7. PubMed ID: 9368913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Changes of depressor responses to bradykinin with preparations blocking kininase and adrenoreceptors].
    Gomazkov OA; Shimkovich MV
    Kardiologiia; 1974 Jul; 14(7):57-66. PubMed ID: 4154383
    [No Abstract]   [Full Text] [Related]  

  • 28. Renin inhibitors.
    Haber E
    N Engl J Med; 1978 May; 298(18):1023-5. PubMed ID: 205787
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of bradykinin in hypertension and the antihypertensive effect of angiotensin-converting enzyme inhibitors.
    Gavras I; Gavras H
    Am J Med Sci; 1988 Apr; 295(4):305-7. PubMed ID: 2834950
    [No Abstract]   [Full Text] [Related]  

  • 30. [Therapeutic drug monitoring of inhibitors of renin-angiotensin system].
    Saito I; Saruta T
    Nihon Rinsho; 1990 Feb; 48 Suppl():1146-8. PubMed ID: 2192113
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers.
    Weber C; Tam YK; Schmidtke-Schrezenmeier G; Jonkmann JH; van Brummelen P
    Eur J Clin Pharmacol; 1996; 51(1):87-90. PubMed ID: 8880057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STOPPING at the CAPPP of good HOPE.
    Luft FC
    Nephrol Dial Transplant; 2000 Apr; 15(4):451-2. PubMed ID: 10727535
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibitors of angiotensin-converting enzyme.
    Cushman DW; Ondetti MA; Cheung HS; Antonaccio MJ; Murthy VS; Rubin B
    Adv Exp Med Biol; 1980; 130():199-225. PubMed ID: 6250340
    [No Abstract]   [Full Text] [Related]  

  • 34. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors.
    Ishihara K; Hayash I; Yamashina S; Majima M
    Jpn J Pharmacol; 2001 Dec; 87(4):318-26. PubMed ID: 11829151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Assessment of acute blood pressure variability during a stress test].
    Mounier-Véhier C; Clerson P; Laude D; Elkohen M; Poncelet P; Goullard L
    Ann Cardiol Angeiol (Paris); 2002 Apr; 51(2):69-75. PubMed ID: 12471685
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pharmacokinetic and pharmacodynamic features of hypertensive drugs in treatment of patients with arterial hypertension associated with liver disease].
    Mikheeva OM
    Eksp Klin Gastroenterol; 2010; (6):95-101. PubMed ID: 20731173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds.
    Kostis JB
    Am J Hypertens; 1989 Jan; 2(1):57-64. PubMed ID: 2643970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of captopril in human blood by an enzyme-linked immunosorbent assay.
    Jehanli AM; Arafat T; al-Shami M
    J Pharm Pharmacol; 1996 Sep; 48(9):914-7. PubMed ID: 8910853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose combinations: A valuable tool to improve adherence to antihypertensive treatment.
    Satsoglou S; Tziomalos K
    J Clin Hypertens (Greenwich); 2018 May; 20(5):908-909. PubMed ID: 29700948
    [No Abstract]   [Full Text] [Related]  

  • 40. Artificial neural network modeling for drug dialyzability prediction.
    Daheb K; Lipman ML; Hildgen P; Roy JJ
    J Pharm Pharm Sci; 2013; 16(5):665-75. PubMed ID: 24393550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.